source
- Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC dealNew follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.BioPharma Dive · 54m ago↗ source
- Rapport Therapeutics' epilepsy drug RAP-219 meets primary endpoint in bipolar mania Phase II trialRapport Therapeutics reported that its experimental pill RAP-219, originally developed for epilepsy, was tested in a mid‑stage study of adults with bipolar mania. The trial enrolled roughly 250 par…